
Responsible of ensuring to control, monitor and record all activities which directly or indirectly impact on all aspects of the product quality, donor suitability and donor safety, as well as plasma testing and plasma warehouse.
Responsible of implementing suitable controls to ensure the accuracy, integrity, availability and legibility of documents.
KEY RESPONSIBILITIES
KEY RESPONSIBILITIES
- Bachelor s Degree in Health-related Sciences.
- Knowledge of Quality Management, as Good Documentation Practices.
- Knowledge of cGMP requirements preferred.
- Typically requires a minimum of 2 years of related experience in GMP Documentation Systems within a Pharmaceutical Company preferred.
- Proficiency in Computers.
- Organized and able to manage time effectively.
- Ability to work within a highly regulated, labor-intensive environment.
- Ability to understand, explain, follow, and enforce SOPs and protocols
- Ability to plan, communicate and execute activities for the improvement of overall operations.
- Written and spoken English and Arabic.

Grifols Egypt for plasma derivatives is a joint-venture (JV) company between the Egyptian Government, through the National Service Projects Organization (NSPO) and Grifols, the global leader in plasma medicines with more than 110 years of contribution to improving the health and well-being of people.
This joint venture is the first of its kind in the plasma industry and the first-ever Egyptian source member of the Plasma Protein Therapeutics Association (PPTA). GEPD is a groundbreaking global public-private alliance that will benefit the entire region.
GEPD is committed to developing the plasma medicines market and achieving self-sufficiency in these critical therapies, which is crucial for the Egyptian healthcare system.
We are combining the expertise of both shareholders to build and operate 20 plasma donation centers throughout Egypt, along with manufacturing facilities including fractionation, purification, and fill-and-finish plants with a processing capacity of up to 1 million liters of plasma annually that can double in the future.
The new manufacturing facility will include a plasma warehouse and a testing laboratory. It will occupy 105,000 square meters strategically located in the administrative capital’s medical city, adjoining various healthcare institutions.